Histone Chaperones and Digestive Cancer: A Review of the Literature

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Nov 26

PMID 36428674

Authors

Zhou Zhao

Zhaolun Cai

Tianxiang Jiang

Junhong Han

Bo Zhang

Affiliations

Soon will be listed here.

Abstract

Background: The global burden of digestive cancer is expected to increase. Therefore, crucial for the prognosis of patients with these tumors is to identify early diagnostic markers or novel therapeutic targets. There is accumulating evidence connecting histone chaperones to the pathogenesis of digestive cancer. Histone chaperones are now broadly defined as a class of proteins that bind histones and regulate nucleosome assembly. Recent studies have demonstrated that multiple histone chaperones are aberrantly expressed and have distinct roles in digestive cancers.

Objective: The purpose of this review is to present the current evidence regarding the role of histone chaperones in digestive cancer, particularly their mechanism in the development and progression of esophageal, gastric, liver, pancreatic, and colorectal cancers. In addition, the prognostic significance of particular histone chaperones in patients with digestive cancer is discussed.

Methods: According to PRISMA guidelines, we searched the PubMed, Embase, and MEDLINE databases to identify studies on histone chaperones and digestive cancer from inception until June 2022.

Results: A total of 104 studies involving 21 histone chaperones were retrieved.

Conclusions: This review confirms the roles and mechanisms of selected histone chaperones in digestive cancer and suggests their significance as potential prognostic biomarkers and therapeutic targets. However, due to their non-specificity, more research on histone chaperones should be conducted in the future to elucidate novel strategies of histone chaperones for prognosis and treatment of digestive cancer.

Citing Articles

Mammalian piRNA target prediction using a hierarchical attention model.

Zhang T, Chen L, Zhu H, Wong G BMC Bioinformatics. 2025; 26(1):50.

PMID: 39934678 PMC: 11817350. DOI: 10.1186/s12859-025-06068-6.

Comparative Review on Cancer Pathology from Aberrant Histone Chaperone Activity.

Lee J, Bao X Int J Mol Sci. 2024; 25(12).

PMID: 38928110 PMC: 11203986. DOI: 10.3390/ijms25126403.

Contribution of histone variants to aneuploidy: a cancer perspective.

Ragusa D, Vagnarelli P Front Genet. 2023; 14:1290903.

PMID: 38075697 PMC: 10702394. DOI: 10.3389/fgene.2023.1290903.

Cancer Epigenetic Biomarkers.

Coppede F Cancers (Basel). 2023; 15(22).

PMID: 38001625 PMC: 10669964. DOI: 10.3390/cancers15225365.

References

Peng H, Du B, Jiang H, Gao J . Over-expression of CHAF1A promotes cell proliferation and apoptosis resistance in glioblastoma cells via AKT/FOXO3a/Bim pathway. Biochem Biophys Res Commun. 2016; 469(4):1111-6. DOI: 10.1016/j.bbrc.2015.12.111. View

Tang J, Chen H, Wong C, Liu D, Li T, Wang X . DEAD-box helicase 27 promotes colorectal cancer growth and metastasis and predicts poor survival in CRC patients. Oncogene. 2018; 37(22):3006-3021. PMC: 5978808. DOI: 10.1038/s41388-018-0196-1. View

Dyer M, Qadeer Z, Valle-Garcia D, Bernstein E . ATRX and DAXX: Mechanisms and Mutations. Cold Spring Harb Perspect Med. 2017; 7(3). PMC: 5334245. DOI: 10.1101/cshperspect.a026567. View

Zhang D, Wu F, Song J, Meng M, Fan X, Lu C . A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma. Cancer Cell Int. 2022; 22(1):65. PMC: 8822852. DOI: 10.1186/s12935-022-02479-0. View

Li X, Oh S, Song H, Shin S, Zhang B, Freeman W . A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer. Oncol Lett. 2018; 16(5):6652-6662. PMC: 6202502. DOI: 10.3892/ol.2018.9487. View

Xu C, Wang Y, Tu Q, Zhang Z, Chen M, Mwangi J . Targeting surface nucleolin induces autophagy-dependent cell death in pancreatic cancer via AMPK activation. Oncogene. 2018; 38(11):1832-1844. DOI: 10.1038/s41388-018-0556-x. View

Lakshmi Ch N, Sivagnanam A, Raja S, Mahalingam S . Molecular basis for RASSF10/NPM/RNF2 feedback cascade-mediated regulation of gastric cancer cell proliferation. J Biol Chem. 2021; 297(2):100935. PMC: 8339327. DOI: 10.1016/j.jbc.2021.100935. View

Hossan T, Nagarajan S, Baumgart S, Xie W, Tirado Magallanes R, Hernandez C . Histone Chaperone SSRP1 is Essential for Wnt Signaling Pathway Activity During Osteoblast Differentiation. Stem Cells. 2016; 34(5):1369-76. DOI: 10.1002/stem.2287. View

Guo C, Su X, Wang W, Xia T, Cao X, Yuan S . NPM1 is a diagnostic and prognostic biomarker associated with the clinicopathological characteristics of gastric cancer. Neoplasma. 2022; 69(4):965-975. DOI: 10.4149/neo_2022_220303N237. View

10.

Wu Y, Li X, Yu J, Bjorkholm M, Xu D . ASF1a inhibition induces p53-dependent growth arrest and senescence of cancer cells. Cell Death Dis. 2019; 10(2):76. PMC: 6349940. DOI: 10.1038/s41419-019-1357-z. View

11.

Gibbons R, Pellagatti A, Garrick D, Wood W, Malik N, Ayyub H . Identification of acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in the alpha-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet. 2003; 34(4):446-9. DOI: 10.1038/ng1213. View

12.

Destouches D, Page N, Hamma-Kourbali Y, Machi V, Chaloin O, Frechault S . A simple approach to cancer therapy afforded by multivalent pseudopeptides that target cell-surface nucleoproteins. Cancer Res. 2011; 71(9):3296-305. DOI: 10.1158/0008-5472.CAN-10-3459. View

13.

Hackeng W, Brosens L, Kim J, OSullivan R, Sung Y, Liu T . Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size. Gut. 2021; 71(5):961-973. PMC: 8511349. DOI: 10.1136/gutjnl-2020-322595. View

14.

Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J . A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol. 2003; 84(1):24-30. DOI: 10.1002/jso.10287. View

15.

Carvalho L, Goncalves N, Fonseca N, Moreira J . Cancer Stem Cells and Nucleolin as Drivers of Carcinogenesis. Pharmaceuticals (Basel). 2021; 14(1). PMC: 7828541. DOI: 10.3390/ph14010060. View

16.

Falini B, Nicoletti I, Martelli M, Mecucci C . Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2006; 109(3):874-85. DOI: 10.1182/blood-2006-07-012252. View

17.

Ching R, Lau E, Ling P, Lee J, Ma M, Cheng B . Phosphorylation of nucleophosmin at threonine 234/237 is associated with HCC metastasis. Oncotarget. 2015; 6(41):43483-95. PMC: 4791245. DOI: 10.18632/oncotarget.5820. View

18.

Liu Y, Guo F, Zhu X, Guo W, Fu T, Wang W . Death Domain-Associated Protein Promotes Colon Cancer Metastasis through Direct Interaction with ZEB1. J Cancer. 2020; 11(3):750-758. PMC: 6959037. DOI: 10.7150/jca.34233. View

19.

Wu R, Li L, Bai Y, Yu B, Xie C, Wu H . The long noncoding RNA LUCAT1 promotes colorectal cancer cell proliferation by antagonizing Nucleolin to regulate MYC expression. Cell Death Dis. 2020; 11(10):908. PMC: 7584667. DOI: 10.1038/s41419-020-03095-4. View

20.

Chen Z, Gao W, Pu L, Zhang L, Han G, Zuo X . PRDM8 exhibits antitumor activities toward hepatocellular carcinoma by targeting NAP1L1. Hepatology. 2018; 68(3):994-1009. DOI: 10.1002/hep.29890. View